Form 4: Medpace CEO Troendle Sells Small Block of Shares

Medpace Holdings, Inc. CEO August J. Troendle reported the sale of 668 shares of common stock at a weighted average price of $590.69.

Summary

• August J. Troendle, CEO, Director, and 10% Owner of Medpace Holdings, Inc. (MEDP), reported a transaction.
• On December 3, 2025, Mr. Troendle disposed of 668 shares of Medpace Holdings, Inc. Common Stock.
• The shares were sold at a weighted average price of $590.69 per share, with individual transactions ranging from $590.00 to $591.61.
• The transaction was executed pursuant to a limit order placed by Mr. Troendle during an open window period.
• Following this transaction, Mr. Troendle directly beneficially owns 646,184 shares of Common Stock.
• Additionally, Mr. Troendle indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.

Sentiment

Score: 5

Explanation: The sentiment is neutral. A Form 4 reports a factual insider transaction. The sale of 668 shares by the CEO, while an insider sale, is a very small amount relative to his total holdings and was executed via a pre-planned limit order, suggesting it's a routine liquidity event rather than a signal of significant concern about the company's prospects.

Positives

• The transaction was conducted pursuant to a pre-placed limit order during an open window period, suggesting a planned and routine sale rather than an urgent or reactive one, which can be viewed as a positive for transparency and adherence to insider trading policies.

Negatives

• While a small amount relative to total holdings, any insider sale, even if pre-planned, can sometimes be interpreted by some investors as a minor signal of reduced confidence, though this is often offset by the routine nature of such transactions.

Risks

• No specific risks to the company's operations or financial health were mentioned in this Form 4 filing, which is solely for reporting insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transactions reported were effected pursuant to a limit order placed by the Reporting Person during an open window period.
• The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

This insider transaction report is specific to Medpace Holdings, Inc. and its CEO, August J. Troendle, and does not provide information directly related to broader industry trends or competitor activities.

Comparison to Industry Standards

• NA

Related Party Transactions

• August J. Troendle indirectly beneficially owns 4,733,019 shares of Medpace Holdings, Inc. through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: May note the insider sale, but given the small volume and pre-planned nature, it is unlikely to significantly alter investment sentiment.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider transaction report.

Next Steps

• No specific future actions, events, or milestones for the company were mentioned in this insider transaction report.

Key Dates

Recommendation

The sale of 668 shares by the CEO, while an insider transaction, represents a negligible portion of his total holdings and was executed as a pre-planned limit order. This type of routine, small-volume insider sale typically does not indicate a material change in the company's fundamentals or future prospects, and therefore does not warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Medpace, MEDP, August J. Troendle, Insider Trading, Form 4, Stock Sale, CEO, Beneficial Ownership